Profit before tax jumped 43.43% to Rs 377.28 crore in Q4 FY23 as compared with Rs 263.04 crore in corresponding quarter last year.

EBITDA stood at Rs 419 crore in Q4 FY23, registering the growth of 45% as compared with Rs 290 crore recorded in Q4 FY22. EBITDA margin was at 20.4% in Q4 FY23 as against 16.8% in Q4 FY22.

Revenue from domestic business jumped 18% to Rs 1,972 crore in Q4 FY23 as compared with Rs 1,677 crore in same quarter last year. During the quarter, chronic segment increased 14% YoY and it contributes 35% of total revenue.

Consumer healthcare business grew 10% YoY to Rs 152 crore in Q4 FY23. Exports business witnessed a growth of 63% YoY to Rs 81 crore in Q4 FY23. The company said that new integrated API/formulation manufacturing plant expected to be commercialized in H1FY24 and it will export Dydrogesterone to key export markets.

On consolidated basis, the company's consolidated net profit declined 10.58% to Rs 1281.85 crore on 12.44% jump in revenue from operations to Rs 8,749.43 crore in FY23 over FY22.

As on 31 March 2023, total capex stood at Rs 832 crore.

Rajeev Juneja, vice chairman & managing director, said, “Our domestic business continued to outperform the IPM in FY23, led by growth in chronic segments whose share has increased to 34% from 33% in FY22. Our consumer healthcare business has maintained its doubledigit growth with dominant brand leadership in its categories.

Our focus is on increasing value of prescription within existing class II-IV and rural markets and increasing penetration in Metros through higher chronic presence. We also plan to leverage our brand dominance to grow our consumer healthcare business, going ahead.”

Mankind Pharma is engaged in manufacturing of pharmaceutical formulations. The company is one of the leading manufacturers of prescription medicines.

The scrip fell 0.86% to Rs 1345.00 on the BSE.